ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc (MDP)

7.75
0.00
( 0.00% )
Updated: 19:00:00

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
7.75
Bid
7.80
Ask
7.85
Volume
-
0.00 Day's Range 0.00
7.75 52 Week Range 7.75
Market Cap
Previous Close
7.75
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
24,458,000
Dividend Yield
-
PE Ratio
-295.40
Earnings Per Share (EPS)
-0.01
Revenue
113.05M
Net Profit
-214k

About Medexus Pharmaceuticals Inc

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Website
Headquarters
Bolton, Gbr
Founded
2013
Medexus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the TSX Venture Exchange with ticker MDP. The last closing price for Medexus Pharmaceuticals was $7.75. Over the last year, Medexus Pharmaceuticals shares have traded in a share price range of $ 7.75 to $ 7.75.

Medexus Pharmaceuticals currently has 24,458,000 shares outstanding. The market capitalization of Medexus Pharmaceuticals is $189.55 million. Medexus Pharmaceuticals has a price to earnings ratio (PE ratio) of -295.40.

MDP Latest News

Complete Response Letter Received from FDA for Treosulfan

TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced...

Medexus Appoints New Chief Financial Officer

TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad...

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in C...

TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered...

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

TORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of...

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021...

Medexus Announces Graduation to the Toronto Stock Exchange

TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final...

Medexus to Present at Raymond James Human Health Innovation Conference

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...

Medexus Schedules Fiscal Year 2021 Conference Call

TORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today...

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it...

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1007.757.757.7500CS
4007.757.757.7500CS
12007.757.757.7500CS
26007.757.757.7500CS
52007.757.757.7500CS
156007.757.757.7500CS
2603.4379.39814814814.329.751.4284776.66976544CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MTXMetalex Ventures Ltd
$ 0.015
(50.00%)
508k
KIBKiboko Gold Inc
$ 0.015
(50.00%)
164k
HBKHighbank Resources Ltd
$ 0.015
(50.00%)
1,000
TVITVI Pacific Inc
$ 0.015
(50.00%)
71k
JADEJade Leader Corp
$ 0.03
(50.00%)
1,000
NUGNulegacy Gold Corporation
$ 0.005
(-50.00%)
10k
EGTEguana Technologies Inc
$ 0.005
(-50.00%)
3k
PPMPacific Imperial Mines Inc
$ 0.01
(-33.33%)
200k
BECNBeacn Wizardry & Magic Inc
$ 0.06
(-33.33%)
15k
CUCUGlobal Copper Corp
$ 0.02
(-33.33%)
3k
VOValOre Metals Corp
$ 0.08
(14.29%)
10.16M
BFMBedford Metals Corp
$ 1.08
(-22.86%)
2.82M
TAJTajiri Resources Corp
$ 0.05
(11.11%)
1.59M
GSVRGuanajuato Silver Company Ltd
$ 0.245
(-2.00%)
1.49M
NBMNEO Battery Materials Ltd
$ 0.28
(14.29%)
1.47M

Discussion

View Full Feed
JohnnyMakeBucks JohnnyMakeBucks 1 minute ago
The TA is really strange on TGRP. They do not give the amount of restricted and free trading shares that represent the outstanding. The other TA’s provide that info. Pretty shady IMO and I don’t know how that’s OTCMarket TA compliant.

You have no idea how many shares can truly hit th
TGRP
noradio noradio 1 minute ago
Aren't most of the restricted shares owned by CEO? Who are these private equity guys and where did you get that information?

Oh wait…. It just happened

It happened? 🤔
TGRP
PirateMeteor67 PirateMeteor67 1 minute ago
The SBC Medical Group deal is HTCR biggest Go IPO deal to date, amassing a gross total of $17.9 million in total top line revenue for HeartCore. HeartCore is slated to have its strongest quarter in corporate history. Relative to last year’s revenue for the first nine-months ended September 30, 2023,
HTCR
ExtremelyBullishZig ExtremelyBullishZig 1 minute ago
I was right, call me George!
AVXL
Carjockey2 Carjockey2 1 minute ago
It's about making money not posting..

LMAO

Missed your own run 🤡
VHAI
CuriousGeorge CuriousGeorge 1 minute ago
That's a crock. You and I both know it.
JNSH
Nosnibor Nosnibor 2 minutes ago
Any news or progress? Who is still investing / holding their bag here?
GSTC
Jetmek_03052 Jetmek_03052 2 minutes ago
No, it isn't. Not according to iHub rules I guess. I frequently attempt to remove his posts. They are idiotic and bring no value to the NVDA board, IMO. However, most of them are invariably restored.
NVDA
Here Today Here Today 2 minutes ago
Exactly. No need to put out false info which makes it look dirty. The Clinical Trial especially the site in TX is most appealing to me since they are top notch for cancer treatments of all types. And trust me -
MD Anderson would love to be the site to say “Hey we have something GOLDEN” here!
RNAZ
learningcurve2020 learningcurve2020 2 minutes ago
Totally false. You shouldn't be a mod.

>>Other than Vera being a director of both, that’s the ONLY thing Marker and AlloVir have in common
MRKR
Saving Grace Saving Grace 2 minutes ago
Hycroft Mining & Dolly Varden Silver: Fireside Chat

https://www.youtube.com/watch?v=y2KoLJhj8YU
HYMC
Carjockey2 Carjockey2 2 minutes ago
LMAO


>>>its called dAY TRADING...DO U UNDERSTAND...>>>

Missed yet your own run..

LMAO 🤣

🤡
VHAI
Steady_T Steady_T 2 minutes ago
There was no advice in my post. A disagreement on the value of the company and it potential. I see your $15 billion buyout price as undervaluing the longer term value of the company.

For a short term investing perspective $30 a share looks pretty good.
For a long term investi
AVXL
Involuntary-Recluse Involuntary-Recluse 2 minutes ago
No sireeeeeeeeeeeeeeeeeeeeeeeeeeeee Bob.

Cowboys Anonymous;

Week 4: Prolong nature walk and watch the wires for ASKH Dividend plan ;-)

imho
ASKH
CrazyC CrazyC 2 minutes ago
BMEA - $9.01 - Worth watching... Little pop on news... 33.8% short interest...

https://finance.yahoo.com/news/fda-lifts-clinical-hold-bmf-180000898.html

https://fintel.io/ss/us/BMEA
BMEA
Moonboy1 Moonboy1 2 minutes ago
Fake out. Not fallout. I can't stand auto correct
SHIBUSD
TrendTrade2016 TrendTrade2016 3 minutes ago
THATS RIGHT...YOU SAID IT CRASHED THO
VHAI
Moonboy1 Moonboy1 3 minutes ago
Is this going to be the biggest fallout of the year?
SHIBUSD
GREGG THE GREEK GREGG THE GREEK 3 minutes ago
We have a saying ...well quite a few.

But every day is not Easter Sunday.

We've had a VERY nice move here this past month on really nothing so I'm feeling great about where we are heading. And once these guys fill us in on more of what's what we SHOULD be trading much
MONI
solidgold solidgold 3 minutes ago
I wanted to say 9 digits volume! NBRI.
NBRI
TrendTrade2016 TrendTrade2016 4 minutes ago
ARQQ...U MISSED ANOTHER
ARQQ
Carjockey2 Carjockey2 4 minutes ago
LMAO what happened to TIMBER..

YOU SOLD TWG..SO THERE IS THAT..

LMAO
TWG
boston745 boston745 4 minutes ago
What rhetoric? The scientific study? The size of the markets Sintx materials can be used in?

In regards to Sintx and NP Aerospace, all we have evidence of is a likely strategic partnership in female body armor development. We dont know if that would include supplying armor panels for
SINT
ironhammer ironhammer 4 minutes ago
very good if it sells down to 001 ill be there to add
NBRI
Rainer Rainer 4 minutes ago
RDAR .0005s going
RDAR